Secondly, tofacitinib as a targeted small molecule inhibitor of several JAK subtypes, acts on synovial JAK/STAT targets through IFN and IL-6 signaling pathways, thus blocking the role of JAK in synovial response to play a therapeutic role in RA [14,17,18]. The gene discussed is IL6; the disease is rheumatoid arthritis.